东方生物董事长方剑秋新年致辞：志在全球化布局，已做好再次扬帆起航的准备

Core Insights - In 2024, the company focused on proactive change and innovative development, achieving significant accomplishments in globalization and R&D registration [1] Globalization Strategy - The company accelerated the construction of production, sales, and research bases in various locations including Anji, Hangzhou, Nanjing, Chengdu, Hainan, Shanghai, and the United States, aiming for early production and effectiveness [2] - Acquisitions included the purchase of Confirm in the U.S. for local retail channel development, and the acquisition of Hangzhou Laihe for complementary capabilities in infectious disease and drug testing [2] - The establishment of a large-scale POCT production base in the U.S. with multiple automated production lines ensures capacity for local orders [2] - A new medical laboratory in the U.S. received CLIA certification, allowing for research and testing services [2] R&D and Product Development - The company established a North American R&D center to enhance technical capabilities and improve production efficiency [3] - Investment in a global digital R&D innovation headquarters in Shanghai aims to develop precision medical instruments and establish a comprehensive molecular diagnostic platform [3] - The company received FDA emergency use authorization for a combined rapid test for COVID-19 and influenza, marking a significant milestone in product registration [4] Regulatory Approvals and Certifications - The company’s drug testing kits received various certifications, including NMPA in China and FDA approvals in the U.S. for multiple products [4][5] - The establishment of a drug monitoring and warning center in collaboration with local authorities highlights the company's commitment to public health [4] Future Outlook - The chairman expressed optimism for 2025, emphasizing the balance of opportunities and challenges ahead, and the company's readiness to embrace the future with determination [5]